Furosemide (F) pharmacodynamics in VLBW infants have not been described following initial and subsequent doses during chronic adminstration. F acts from the luminal side of the loop of Henle and there ...

We have previously demonstrated an apparent decrease in renal tubular secretion and an increase in plasma half-life for furosemide (F) in VLBW infants. To pharmacokinetically characterize maturation ...

Findings from an open-label study evaluating the effect of sacubitril/valsartan on the pharmacokinetics (PK) and pharmacodynamics (PD) of furosemide showed no significant impact among healthy patients ...

The autoinjector is being developed to deliver a subcutaneous injection of furosemide as an alternative option to the FDA approved FUROSCIX on-body infusor presentation Company targeting Supplemental ...